Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Semaglutide/Tirzepatide Benefits: More Semaglutide/Tirzepatide Benefits: Cardiovascular Benefits Semaglutide and Tirzepatide have shown cardiovascular benefits beyond weight loss and glycemic control
To qualify for Wegovy, youll typically need one of the following: A BMI of 30 or higher (classified as obesity ), or A BMI of 27 or higher with at least one weight-related health condition Weight-related conditions may include: High blood pressure (hypertension) High cholesterol (dyslipidemia) Type 2 diabetes Heart disease Obstructive sleep apnea Polycystic ovary syndrome ( PCOS ) In addition, in March 2024 the FDA expanded Wegovys approval to include reducing the risk of major cardiovascular events like heart attac k, stroke, and cardiovascular death in adults with cardiovascular disease plus overweight or obesity
Suspected adverse events should be reported to the FDA MedWatch program to improve post-marketing surveillance
This was a study published in the New England Journal of Medicine, October 2024, One Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. Knee osteoarthritis is seen in 20% of those over the age of 45
Final weight loss outcomes were not significantly affected by a slower titration schedule
Significant appetite suppression can lead to inadequate protein intake, micronutrient deficiencies, and muscle mass loss if dietary composition is not actively managed
